Bettencourt, PauloFonseca, CândidaFranco, FátimaAndrade, AuroraBrito, Dulce2023-02-102023-02-102017-120870-2551PURE: 3389493PURE UUID: 1292c66b-241e-4b82-b5b7-8a4ed0e1b5efPubMed: 29225105WOS: 000418406200002Scopus: 85042474544http://hdl.handle.net/10362/149007Copyright © 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.Assessment of serum levels of natriuretic peptides, especially the amino-terminal portion (NT-proBNP) and the carboxy-terminal portion (BNP) of pro-B-type natriuretic peptide, has had a highly significant clinical impact on the diagnosis and prognostic stratification of patients with heart failure (HF). They are now an instrument with recognized value in this context and several studies have demonstrated their value in tailoring therapy for these patients. Following the recent advent of angiotensin receptor-neprilysin inhibitors (ARNIs), there is a need to review how these two biomarkers are interpreted in HF. The use of ARNIs is associated with a reduction in NT-proBNP but an increase in BNP levels. The authors of this concise article review the interpretation of natriuretic peptide levels in the light of the most recent evidence.4430554porHeart failureNatriuretic peptidesB-type natriuretic peptideNT-proBNPjournal article10.1016/j.repc.2017.09.014